Skip to main content
SpringerLink
Log in

BPH/LUTS: Heart Healthy = Prostate Healthy

  • Chapter
  • First Online:
Book cover Complementary & Alternative Medicine for Prostate and Urologic Health

  • 919 Accesses

Abstract

Aging, genetics, and a family history of BPH/LUTS can profoundly increase the risk of these conditions. Yet the observation that prescription alpha-blocker (originally designed to reduce blood pressure) medications could quickly reduce BPH severity for some men, along with decades of lifestyle research, now suggests that BPH prevention and perhaps partial treatment may occur via heart-healthy processes. Almost all documented heart-healthy interventions or lifestyle changes can prevent some aspect of BPH/LUTS. Moderate alcohol intake, blood pressure, glucose, lipid, caloric, and weight control, and exercise and increased vegetable, fiber, and plant omega-3 intakes are just some of the many lifestyle factors that are gaining consistent data to suggest that this condition can be prevented, delayed, and partially treated with heart-healthy behaviors. However, heart-unhealthy lifestyle changes could also lead to profound increases in the risk and need for treatment for BPH/LUTS. The time is now for clinicians to embrace, practice, and promote heart-healthy behaviors to men concerned about BPH/LUTS. Heart health equals prostate health. This mantra is easy to say but difficult to comply with, which is why there is a need to constantly emphasize the overwhelming amount of old and new data that suggest that BPH/LUTS is a lifestyle-impacted condition for many men around the world.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Moyad MA. Lifestyle changes to prevent BPH: heart-healthy=prostate healthy. Urol Nurs. 2003;23:439–41.

    PubMed  Google Scholar 

  2. Moyad MA, Lowe FC. Educating patients about lifestyle modifications for prostate health. Am J Med. 2008;121(8 Suppl 2):S34–42.

    Article  PubMed  Google Scholar 

  3. Kupelian V, McVary KT, Barry MJ, Link CL, Rosen RC, Aiyer LP, et al. Association of C-reactive protein and lower urinary tract symptoms in men and women: results from Boston Area Community Health Survey. Urology. 2009;73:950–7.

    Article  PubMed  Google Scholar 

  4. Partin AW, Page WF, Lee BR, Sanda MG, Miller RN, Walsh PC. Concordance rates for benign prostatic disease among twins suggest hereditary influence. Urology. 1994;44:646–50.

    Article  PubMed  CAS  Google Scholar 

  5. Sanda MG, Beaty TH, Stutzman RE, Childs B, Walsh PC. Genetic susceptibility of benign prostatic hyperplasia. J Urol. 1994;152:115–9.

    PubMed  CAS  Google Scholar 

  6. Sanda MG, Doehring CB, Binkowitz B, Beaty TH, Partin AW, Hale E, et al. Clinical and biological characteristics of familial benign prostatic hyperplasia. J Urol. 1997;157:876–9.

    Article  PubMed  CAS  Google Scholar 

  7. Rohrmann S, Fallin MD, Page WF, Reed T, Partin AW, Walsh PC, et al. Concordance rates and modifiable risk factors for lower urinary tract symptoms in twins. Epidemiology. 2006;17:419–27.

    Article  PubMed  Google Scholar 

  8. Faruque MS, Alam MK, Ullah MA, Rahman MH, Kibria MG, Haque MM, et al. Evaluation of transurethral ethanol ablation of prostate for symptomatic benign prostatic hyperplasia. Mymensingh Med J. 2012;21:265–9.

    PubMed  CAS  Google Scholar 

  9. Goya N, Ishikawa N, Ito F, Ryoji O, Tokumoto T, Toma H, Yamaguchi Y. Ethanol injection therapy of the prostate for benign prostatic hyperplasia: preliminary report on application of a new technique. J Urol. 1999;162:383–6.

    Article  PubMed  CAS  Google Scholar 

  10. Savoca G, De Stefani S, Gattuccio I, Paolinelli D, Stacul F, Belgrano E. Percutaneous ethanol injection of the prostate as minimally invasive treatment for benign prostatic hyperplasia: preliminary report. Eur Urol. 2001;40:504–8.

    Article  PubMed  CAS  Google Scholar 

  11. Platz EA, Rimm EB, Kawachi I, Colditz GA, Stampfer MJ, Willett WC, et al. Alcohol consumption, cigarette smoking, and risk of benign prostatic hyperplasia. Am J Epidemiol. 1999;149:106–15.

    Article  PubMed  CAS  Google Scholar 

  12. Gass R. Benign prostatic hyperplasia: the opposite effects of alcohol and coffee intake. BJU Int. 2002;90:649–54.

    Article  PubMed  CAS  Google Scholar 

  13. Crispo A, Talamini R, Gallus S, Negri E, Gallo A, Bosetti C, et al. Alcohol and the risk of prostate cancer and benign prostatic hyperplasia. Urology. 2004;64:717–22.

    Article  PubMed  Google Scholar 

  14. Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, Goodman P, Penson DF, et al. Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol. 2008;167:925–34.

    Article  PubMed  Google Scholar 

  15. Lee YJ, Jeong SJ, Byun SS, Lee JJ, Han JW, Kim KW. Prevalence and correlates of nocturia in community-dwelling older men: results from the Korean Longitudinal Study on Health and Aging. Korean J Urol. 2012;53:263–7.

    Article  PubMed  Google Scholar 

  16. Parsons JK, Im R. Alcohol consumption is associated with a decreased risk of benign prostatic hyperplasia. J Urol. 2009;182:1463–8.

    Article  PubMed  Google Scholar 

  17. Shen W, Yao HQ, Deng ZX, Zhang XM, Zhang LC, Hu WL. Arteriosclerotic risk factors and benign prostatic hyperplasia. Zhonghua Nan Ke Xue. 2010;16:29–33.

    PubMed  CAS  Google Scholar 

  18. de Mey C. Cardiovascular effects of alpha-blockers used for the treatment of symptomatic BPH: impact on safety and well-being. Eur Urol. 1998;34 Suppl 2:18–28.

    Article  Google Scholar 

  19. Abdollah F, Briganti A, Suardi N, Castiglione F, Gallina A, Capitanio U, et al. Metabolic syndrome and benign prostatic hyperplasia: evidence of a potential relationship, hypothesized etiology, and prevention. Korean J Urol. 2011;52:507–16.

    Article  PubMed  Google Scholar 

  20. Zhang X, Zhang J, Chen J, Zhang C, Li Q, Xu T, et al. Prevalence and risk factors of nocturia and nocturia-related quality of life in the Chinese population. Urol Int. 2011;86:173–8.

    Article  PubMed  Google Scholar 

  21. Bravi F, Bosetti C, Dal Maso L, Talamini R, Montella M, Negri E, et al. Food groups and risk of benign prostatic hyperplasia. Urology. 2006;67:73–9.

    Article  PubMed  Google Scholar 

  22. Prezioso D, Catuogno C, Galassi P, D’Andrea G, Castello G, Pirritano D. Life-style in patients with LUTS suggestive of BPH. Eur Urol. 2001;40 Suppl 1:9–12.

    Article  PubMed  Google Scholar 

  23. Signorello LB, Tzonou A, Lagiou P, Sarnoli E, Zavitsanos X, Trichopoulos D. The epidemiology of benign prostatic hyperplasia: a study in Greece. BJU Int. 1999;84:286–91.

    Article  PubMed  CAS  Google Scholar 

  24. Patil H, Lavie CJ, O’Keefe JH. Cuppa joe: friend or foe? Effects of chronic coffee consumption on cardiovascular and brain health. Mo Med. 2011;108:431–8.

    PubMed  Google Scholar 

  25. Heilbronn LK, Ravussin E. Calorie restriction and aging: review of the literature and implications for studies in humans. Am J Clin Nutr. 2003;78:361–9.

    PubMed  CAS  Google Scholar 

  26. Varady KA, Roohk DJ, Hellerstein MK. Dose effects of modified alternate-day fasting regimens on in vivo proliferation and plasma insulin-like growth factor-1 in mice. J Appl Physiol. 2007;103:547–51.

    Article  PubMed  CAS  Google Scholar 

  27. Blando J, Moore T, Hursting S, Jiang G, Saha G, Beltran L, et al. Dietary energy balance modulates prostate cancer progression in Hi-Myc mice. Cancer Prev Res (Phila). 2011;4:2002–14.

    Article  CAS  Google Scholar 

  28. Kristal AR, Chi C, Tangen CM, Goodman PJ, Etzioni R, Thompson IM. Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase. Cancer. 2006;106:320–8.

    Article  PubMed  Google Scholar 

  29. Khoo J, Piantadosi C, Duncan R, Worthley SG, Jenkins A, Noakes M, et al. Comparing effects of a low-energy diet and a high-protein low-fat diet on sexual and endothelial function, urinary tract symptoms, and inflammation in obese diabetic men. J Sex Med. 2011;8:2868–75.

    Article  PubMed  CAS  Google Scholar 

  30. Coker RH, Williams RH, Yeo SE, Kortebein PM, Bodenner DL, Kern PA, et al. The impact of exercise training compared to caloric restriction on hepatic and peripheral insulin resistance in obesity. J Clin Endocrinol Metab. 2009;94:4258–66.

    Article  PubMed  CAS  Google Scholar 

  31. Parsons JK, Bergstrom J, Barrett-Connor E. Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community-dwelling men. BJU Int. 2008;101:313–8.

    Article  PubMed  CAS  Google Scholar 

  32. Freeman MR, Solomon KR. Cholesterol and benign prostate disease. Differentiation. 2011;82:244–52.

    Article  PubMed  CAS  Google Scholar 

  33. Rohrmann S, De Marzo AM, Smit E, Giovannucci E, Platz EA. Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES III). Prostate. 2005;62:27–33.

    Article  PubMed  CAS  Google Scholar 

  34. Sutcliffe S, Giovannucci E, De Marzo AM, Willett WC, Platz EA. Sexually transmitted infections, prostatitis, ejaculation frequency and the odds of lower urinary tract symptoms. Am J Epidemiol. 2005;162:898–906.

    Article  PubMed  Google Scholar 

  35. Sutcliffe S, Rohrmann S, Giovannucci E, Nelson KE, De Marzo AM, Issacs WB, et al. Viral infections and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey. J Urol. 2007;178:2181–5.

    Article  PubMed  Google Scholar 

  36. St Sauver JL, Jacobson DJ, McGree ME, Lieber MM, Jacobsen SJ. Protective association between nonsteroidal anti-inflammatory drug use and measures of benign prostatic hyperplasia. Am J Epidemiol. 2006;164:760–8.

    Article  PubMed  Google Scholar 

  37. Falahatkar S, Mokhtari G, Pourreza F, Asgari SA, Kamran AN. Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled study. Urology. 2008;72:813–6.

    Article  PubMed  Google Scholar 

  38. Padayatty SJ, Marcelli M, Shao TC, Cunningham GR. Lovastatin-induced apoptosis in prostate stromal cells. J Clin Endocrinol Metab. 1997;82:1434–9.

    Article  PubMed  CAS  Google Scholar 

  39. Marino G, Pugno E, Cevoli R, Griffa D, Pastorini S, Cocimano V. Phamracologic treatment of benign prostatic hypertrophy (BPH): a combination of mepartricin and simvastatin. Analysis and results. Minerva Urol Nefrol. 1991;43:279–82.

    PubMed  CAS  Google Scholar 

  40. Stamatiou KN, Zaglavira P, Skolarikos A, Sofras F. The effects of lovastatin on conventional medical treatment of lower urinary tract symptoms with finasteride. Int Braz J Urol. 2008;34:555–61.

    Article  PubMed  Google Scholar 

  41. Kim WT, Yun SJ, Choi YD, Kim GY, Moon SK, Choi YH, et al. Prostate size correlates with fasting blood glucose in non-diabetic benign prostatic hyperplasia patients with normal testosterone levels. J Korean Med Sci. 2011;26:1214–8.

    Article  PubMed  CAS  Google Scholar 

  42. Parsons JK, Carter HB, Partin AW, Windham BG, Metter EJ, Ferrucci L, et al. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab. 2006;91:2562–8.

    Article  PubMed  CAS  Google Scholar 

  43. Parson JK. Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems. J Urol. 2007;178:395–401.

    Article  Google Scholar 

  44. Hammarsten J, Hogstedt B. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press. 1999;8:29–36.

    Article  PubMed  CAS  Google Scholar 

  45. Hammarsten J, Hogstedt B. Calculated fast-growing benign prostatic hyperplasia—a risk factor for developing clinical prostate cancer. Scand J Urol Nephrol. 2002;36:330–8.

    Article  PubMed  Google Scholar 

  46. Sarma AV, St Sauver JL, Hollingsworth JM, Jacobson DJ, McGree ME, Dunn RL, et al. Diabetes treatment and progression of benign prostatic hyperplasia in community-dwelling black and white men. Urology. 2012;79:102–8.

    Article  PubMed  Google Scholar 

  47. Wang Z, Olumi AF. Diabetes, growth hormone-insulin-like growth factor pathways and association to benign prostatic hyperplasia. Differentiation. 2011;82:261–71.

    Article  PubMed  CAS  Google Scholar 

  48. Cohen P, Peehl DM, Baker B, Liu F, Hintz RL, Rosenfeld RG. Insulin-like growth factor axis abnormalities in prostate stromal cells from patients with benign prostatic hyperplasia. J Clin Endocrinol Metab. 1994;79:1410–5.

    Article  PubMed  CAS  Google Scholar 

  49. Boudon C, Rodier G, Lechevallier E, Mottet N, Barenton B, Sultan C. Secretion of insulin-like growth factors and their binding proteins by human normal and hyperplastic prostatic cells in primary culture. J Clin Endocrinol Metab. 1996;81:612–7.

    Article  PubMed  CAS  Google Scholar 

  50. Wang Z, Ikeda K, Wada Y, Foster HE, Weiss RM, Latifpour J. Expression and localization of basic fibroblast growth factor in diabetic rat prostate. BJU Int. 2000;85:945–52.

    Article  PubMed  CAS  Google Scholar 

  51. Park Y, Subar AF, Hollenbeck A, Schatzkin A. Dietary fiber intake and mortality in the NIH-AARP diet and health study. Arch Intern Med. 2011;171: 1061–8.

    Article  PubMed  Google Scholar 

  52. Eshak ES, Iso H, Date C, Kikuchi S, Watanabe Y, Wada Y, et al. Dietary fiber intake is associated with reduced risk of mortality from cardiovascular disease among Japanese men and women. J Nutr. 2010;140:1445–53.

    Article  PubMed  CAS  Google Scholar 

  53. Moreyra AE, Wilson AC, Koraym A. Effect of combining psyllium fiber with simvastatin in lowering cholesterol. Arch Intern Med. 2005;165: 1161–6.

    Article  PubMed  CAS  Google Scholar 

  54. Agrawal AR, Tandon M, Sharma PL. Effect of combining viscous fibre with lovastatin on serum lipids in normal human subjects. Int J Clin Pract. 2007;61:1812–8.

    Article  PubMed  CAS  Google Scholar 

  55. Streppel MT, Arends LR, van’t Veer P, Grobbee DE, Geleijnse JM. Dietary fiber and blood pressure: a meta-analysis of randomized placebo-controlled trials. Arch Intern Med. 2005;165:150–6.

    Article  PubMed  Google Scholar 

  56. Vernay M, Aidara M, Salanave B, Deschamps V, Malon A, Oleko A, et al. Diet and blood pressure in 18–74 year old adults: the French Nutrition and Health Survey (ENNS, 2006–2007). J Hypertens. 2012;30(10):1920–7.

    Article  PubMed  CAS  Google Scholar 

  57. Marlett JA, McBurney MI, Slavin JL, for the American Dietetic Association. Position of the American Dietetic Association: health implications of dietary fiber. J Am Diet Assoc. 2002;102: 993–1000.

    Article  PubMed  Google Scholar 

  58. Kaczmarczyk MM, Miller MJ, Freund GG. The health benefits of dietary fiber: beyond the usual suspects of type 2 diabetes mellitus, cardiovascular disease and colon cancer. Metabolism. 2012;61:1058–66.

    Article  PubMed  CAS  Google Scholar 

  59. Barnard RJ, Kobayashi N, Aronson WJ. Effect of diet and exercise intervention on the growth of prostate epithelial cells. Prostate Cancer Prostatic Dis. 2008;11:362–6.

    Article  PubMed  CAS  Google Scholar 

  60. Tariq N, Jenkins DJA, Vidgen E, et al. Effect of soluble fiber diets on serum prostate specific antigen in men. J Urol. 2000;163:114–8.

    Article  PubMed  CAS  Google Scholar 

  61. Pan A, Yu D, Demark-Wahnefried W, Franco OH, Lin X. Meta-analysis of the effects of flaxseed interventions on blood lipids. Am J Clin Nutr. 2009;90: 288–97.

    Article  PubMed  CAS  Google Scholar 

  62. Rodriguez-Leyva D, Dupasquier CM, McCullough R, Pierce GN. The cardiovascular effects of flaxseed and its omega-3 fatty acid, alpha-linolenic acid. Can J Cardiol. 2010;26:489–96.

    Article  PubMed  Google Scholar 

  63. Bravi F, Bosetti C, Dal Maso L, Talmini R, Montella M, Negri E, et al. Macronutrients, fatty acids, cholesterol, and risk of benign prostatic hyperplasia. Urology. 2006;67:1205–11.

    Article  PubMed  Google Scholar 

  64. Denmark-Wahnefried W, Robertson CN, Walther PJ, Polascik TJ, Paulson DF, Vollmer RT. Pilot study to explore effects of low-fat, flaxseed-supplemented diet on proliferation on benign prostatic epithelium and prostate-specific antigen. Urology. 2004;63:900–4.

    Article  Google Scholar 

  65. Demark-Wahnefried W, Polascik TJ, George SL, Switzer BR, Madden JF, Ruffin IV MT, et al. Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery. Cancer Epidemiol Biomarkers Prev. 2008;17:3577–87.

    Article  PubMed  CAS  Google Scholar 

  66. Zhang W, Wang X, Liu Y, Tian H, Flickinger B, Empie MW, et al. Effects of dietary flaxseed lignan extract on symptoms of benign prostatic hyperplasia. J Med Food. 2008;11:207–14.

    Article  PubMed  CAS  Google Scholar 

  67. Zhang W, Wang X, Liu Y, Tian H, Flickinger B, Empie MW, Sun SZ. Dietary flaxseed lignan extract lowers plasma cholesterol and glucose concentrations in hypercholesterolaemic subjects. Br J Nutr. 2008;99:1301–19.

    PubMed  CAS  Google Scholar 

  68. Fukumitsu S, Aida K, Shimizu H, Toyoda K. Flaxseed lignan lowers blood cholesterol and decreases liver disease risk factors in moderately hypercholesterolemic men. Nutr Res. 2010;30:441–6.

    Article  PubMed  CAS  Google Scholar 

  69. Moyad MA. No bogus science health advice. Ann Arbor, MI: Spry; 2010.

    Google Scholar 

  70. Geller J, Sionit L, Partido C, Li L, Tan X, Youngkin T, et al. Genistein inhibits the growth of human-patient BPH and prostate cancer in histoculture. Prostate. 1998;34:75–9.

    Article  PubMed  CAS  Google Scholar 

  71. Ambrosini GL, de Klerk NH, Mackerras D, Leavy J, Fritschi L. Dietary patterns and surgically treated benign prostatic hyperplasia: a case control study in Western Australia. BJU Int. 2008;101:853–60.

    Article  PubMed  Google Scholar 

  72. Wong WC, Wong EL, Li H, You JH, Ho S, Woo J, et al. Isoflavones in treating watchful waiting benign prostate hyperplasia: a double-blinded, randomized controlled trial. J Altern Complement Med. 2012;18:54–60.

    Article  PubMed  Google Scholar 

  73. Anderson JW, Bush HM. Soy protein effects on serum lipoproteins: a quality assessment and meta-analysis of randomized, controlled studies. J Am Coll Nutr. 2011;30:79–91.

    Article  PubMed  CAS  Google Scholar 

  74. Erdman Jr JW. Soy protein and cardiovascular disease: a statement for healthcare professionals from the nutrition committee of the AHA. Circulation. 2000;102:2555–9.

    Article  PubMed  CAS  Google Scholar 

  75. Sacks FM, Lichtenstein A, Van Horn L, Harris W, Kris-Etherton P, Winston M, et al. Soy protein, isoflavones, and cardiovascular health: an American Heart Association Science Advisory for professionals from the Nutrition Committee. Circulation. 2006;113:1034–44.

    Article  PubMed  CAS  Google Scholar 

  76. Hamilton-Reeves JM, Vazquez G, Duval SJ, Phipps WR, Kurzer MS, Messina MJ. Clinical studies show no effects of soy protein or isoflavones on reproductive hormones in men: results of a meta-analysis. Fertil Steril. 2010;94:997–1007.

    Article  PubMed  CAS  Google Scholar 

  77. Demark-Wahnefried W, Price DT, Polascik TJ, Robertson CN, Anderson EE, Paulson DF, et al. Pilot study of dietary fat restriction and flaxseed supplementation in men with prostate cancer before surgery: exploring the effects of hormonal levels, prostate-specific antigen, and histopathologic features. Urology. 2001;58:47–52.

    Article  PubMed  CAS  Google Scholar 

  78. Rohrmann S, Giovannucci E, Willett WC, Platz EA. Fruit and vegetable consumption, intake of nutrients, and benign prostatic hyperplasia in US men. Am J Clin Nutr. 2007;85:523–9.

    PubMed  CAS  Google Scholar 

  79. Galeone C, Pelucchi C, Talamini R, Negri E, Dal Maso L, Montella M, et al. Onion and garlic intake and the odds of benign prostatic hyperplasia. Urology. 2007;70:672–6.

    Article  PubMed  Google Scholar 

  80. Araki H, Watanabe H, Mishina T, Nakao M. High-risk group for benign prostatic hypertrophy. Prostate. 1983;4:253–64.

    Article  PubMed  CAS  Google Scholar 

  81. Gu F. Changes in the prevalence of benign prostatic hyperplasia in China. Chin Med J (Engl). 1997;110:163–6.

    CAS  Google Scholar 

  82. Parsons JK, Kashefi C. Physical activity, benign prostatic hyperplasia, and lower urinary tract symptoms. Eur Urol. 2008;53:1228–35.

    Article  PubMed  Google Scholar 

  83. Giovannucci E, Rimm EB, Chute CG, Kawachi I, Colditz GA, Stampfer MJ, et al. Obesity and benign prostatic hyperplasia. Am J Epidemiol. 1994;140: 989–1002.

    PubMed  CAS  Google Scholar 

  84. Platz EA, Kawachi I, Rimm EB, Colditz GA, Stampfer MJ, Willett WC, et al. Physical activity and benign prostatic hyperplasia. Arch Intern Med. 1998;158:2349–56.

    Article  PubMed  CAS  Google Scholar 

  85. Gann PH, Hennekens CH, Longcope C, Verhoek-Ottedahl W, Grodstein F, Stampfer MJ. A prospective study of plasma hormone levels, nonhormonal factors, and development of benign prostatic hyperplasia. Prostate. 1995;26:40–9.

    Article  PubMed  CAS  Google Scholar 

  86. Meigs JB, Mohr B, Barry MJ, Collins MM, McKinlay JB. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol. 2001;54:935–44.

    Article  PubMed  CAS  Google Scholar 

  87. Jung S, Lee EN, Lee SR, Kim MS, Lee MS. Tai chi for lower urinary tract symptoms and quality of life in elderly patients with benign prostate hypertrophy: a randomized controlled trial. Evid Based Complement Alternat Med. 2012;2012: 624692.

    PubMed  Google Scholar 

  88. Yeh GY, Wang C, Wayne PM, Phillips RS. The effect of tai chi exercise on blood pressure: a systematic review. Prev Cardiol. 2008;11:82–9.

    Article  PubMed  Google Scholar 

  89. Nguyen MH, Kruse A. A randomized controlled trial of Tai chi for balance, sleep quality and cognitive performance in elderly Vietnamese. Clin Interv Aging. 2012;7:185–90.

    Article  PubMed  CAS  Google Scholar 

  90. Sea J, Poon KS, McVary KT. Review of exercise and the risk of benign prostatic hyperplasia. Phys Sportsmed. 2009;37:75–83.

    Article  PubMed  Google Scholar 

  91. Kang D, Andriole GL, Van De Vooren RC, Crawford D, Chia D, Urban DA, et al. Risk behaviours and benign prostatic hyperplasia. BJU Int. 2004;93: 1241–5.

    Article  PubMed  CAS  Google Scholar 

  92. Sarma AV, Jacobson DJ, St Sauver JL, Lieber MM, Girman CJ, Nehra A, et al. Smoking and acute urinary retention: the Olmsted County study of urinary symptoms and health status among men. Prostate. 2009;69:699–705.

    Article  PubMed  Google Scholar 

  93. Yun AJ, Doux JD. Opening the floodgates: benign prostatic hyperplasia may represent another disease in the compendium of ailments caused by global sympathetic bias that emerges with aging. Med Hypotheses. 2006;67:392–4.

    Article  PubMed  Google Scholar 

  94. Fagerstrom K. The epidemiology of smoking: health consequences and benefits of cessation. Drugs. 2002;62 Suppl 2:1–9.

    Article  PubMed  Google Scholar 

  95. Park HY, Sin D. Smoking kills, quitting heals: the importance of smoking cessation in COPD. Clin Respir J. 2011;5:185–6.

    Article  PubMed  Google Scholar 

  96. Parsons JK, Sarma AV, McVary K, Wei JT. Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions. J Urol. 2009;182(6 Suppl):S27–31.

    Article  PubMed  Google Scholar 

  97. Lee RK, Chung D, Chughtai B, Te AE, Kaplan SA. Central obesity as measured by waist circumference is predictive of severity of lower urinary tract symptoms. BJU Int. 2012;110:540–5.

    Article  PubMed  Google Scholar 

  98. Khoo J, Piantadosi C, Worthley S, Wittert GA. Effects of a low-energy diet on sexual function and lower urinary tract symptoms in obese men. Int J Obes (Lond). 2010;34:1396–403.

    Article  CAS  Google Scholar 

  99. Berger AP, Bartsch G, Deibl M, Alber H, Pachinger O, Fritsche G, et al. BJU Int. 2006;98: 1038–42.

    Article  PubMed  Google Scholar 

  100. Fowke JH, Munro H, Signorello LB, Blot WJ, Penson DF, Urologic Diseases of America Project. Association between socioeconomic status (SES) and lower urinary tract symptom (LUTS) severity among black and white men. J Gen Intern Med. 2011;26:1305–10.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University of Michigan Medical Center, Ann Arbor, MI, USA

    Mark A. Moyad M.D., M.P.H.

Authors
  1. Mark A. Moyad M.D., M.P.H.
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Moyad, M.A. (2014). BPH/LUTS: Heart Healthy = Prostate Healthy. In: Complementary & Alternative Medicine for Prostate and Urologic Health. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-8492-9_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-8492-9_2

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-8491-2

  • Online ISBN: 978-1-4614-8492-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation